This study investigated the cardiovascular (CV) safety profile of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin versus comparator treatments. ⋯ These results from a large Phase 3 programme support the hypothesis that linagliptin may have CV benefits in patients with T2DM.
read on…
or not…